Azithromycin: characteristics and clinical indications for bacterial and virus infections, including SARS-CoV-2 infections
| Autor: | Paulo Melo Júnior, Felipe Leonardo de Melo Almeida Fonseca, Alexandrino Pereira dos Santos Neto, Sandra Maria Alves Sayão Maia, Hadassa Fonsêca da Silva, Luciano Barreto Silva, Douglas José Abreu da Silva Cristovam, Gabriel Henrique Queiroz Oliveira, Ailton Coelho de Ataíde Filho, Guilherme Marinho Sampaio, Rodolfo Scavuzzi Carneiro Cunha |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19) medicine.drug_class business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Antibiotics Hydroxychloroquine Cochrane Library Azithromycin Virus Clinical trial medicine General Earth and Planetary Sciences Intensive care medicine business General Environmental Science medicine.drug |
| Zdroj: | Research, Society and Development. 10:e381101219864 |
| ISSN: | 2525-3409 |
| Popis: | Objective: to accomplish a literature review to research the clinical characteristics of azythromycin, and its indications and associations for SARS-CoV-2 infections. Methodology: Electronic searches were carried out on PUBMED Central, BVS/BIREME, Web of Science and The Cochrane Library with the aid of key-words. Results: Azithromycin is a secure antibiotic belonging to the macrolide class, effective for a vast number of infections, especially respiratory diseases. It seems to have viral indirect activity due to its being capable of altering the cell machinery, including mitochondrias, for changing the normal functioning of mitochondrial ribosomes. Conclusion: It is uncertain whether azithromycin is eligible for the treatment of virus infections in general and especially for COVID-19. Its combination with hydroxychloroquine, however, should be better researched in order to answer if it can be applied as a clinical approach for this matter. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|